- Shares of Omeros (OMER +53.2%) skyrocket as Wedbush raises its price target to $28 from $18.
- Back in August, Liana Moussatos put the odds of the FDA accepting the company's OMS302 NDA for review at 90% (that expectation is reiterated today).
- After speaking to a "high-volume cataract surgeon," Moussatos has apparently decided to double U.S. penetration estimates for the phenylephrine/ ketorolac combo, developed for the maintenance of pupil dilation, prevention of pupil constriction, and reduction of postoperative ocular pain.
- The rationale: FDA scrutiny of sterility issues in topical solutions used during intraocular lens replacement surgery should drive up prices on topical NSAIDs and mydriatic agents, making OMS302 price competitive.
Omeros soars on Wedbush OMS302 call
Sep 16 2013, 11:09 ET